BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts ...
AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more ...
Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for ...
Shares of AtaiBeckley Inc ATAI continued to rally in early trading on Tuesday after it released Phase 2 trial data for BPL-003 for the treatment of social anxiety disorder. Here are the key analyst ...
Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts ...
Continued pipeline progress, including positive Phase 2a results for EMP‑01 and expected Phase 2 topline for VLS-01 in H2 2026 Replay and presentation materials available on AtaiBeckley’s investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results